NFKB1 and systemic lupus erythematosus: Inhibition of the activity of the IRAK1-TRAF6-NF-κB pathway ameliorates SLE by attenuating macrophage activity and reducing the overproduction of macrophage inflammatory factors such as IL-1β, IL-6, and TNF-α [112].